These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38128233)

  • 1. Tumor-homing peptide iRGD-conjugate enhances tumor accumulation of camptothecin for colon cancer therapy.
    Singh T; Kim TW; Murthy ASN; Paul M; Sepay N; Jeong Kong H; Sung Ryu J; Rim Koo N; Yoon S; Song KH; Jun Baek M; Jeon S; Im J
    Eur J Med Chem; 2024 Feb; 265():116050. PubMed ID: 38128233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery.
    Ma L; Chen Q; Ma P; Han MK; Xu Z; Kang Y; Xiao B; Merlin D
    Nanomedicine (Lond); 2017 Aug; 12(16):1991-2006. PubMed ID: 28745123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved tumor targeting and antitumor activity of camptothecin loaded solid lipid nanoparticles by preinjection of blank solid lipid nanoparticles.
    Jang DJ; Moon C; Oh E
    Biomed Pharmacother; 2016 May; 80():162-172. PubMed ID: 27133053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A silica-based antioxidant nanoparticle for oral delivery of Camptothecin which reduces intestinal side effects while improving drug efficacy for colon cancer treatment.
    Nguyen-Trinh QN; Trinh KXT; Trinh NT; Vo VT; Li N; Nagasaki Y; Vong LB
    Acta Biomater; 2022 Apr; 143():459-470. PubMed ID: 35235866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment.
    Zhong Y; Su T; Shi Q; Feng Y; Tao Z; Huang Q; Li L; Hu L; Li S; Tan H; Liu S; Yang H
    Int J Nanomedicine; 2019; 14():8543-8560. PubMed ID: 31802868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
    Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
    J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theranostic iRGD peptide containing cisplatin prodrug: Dual-cargo tumor penetration for improved imaging and therapy.
    Cho HJ; Park SJ; Lee YS; Kim S
    J Control Release; 2019 Apr; 300():73-80. PubMed ID: 30831135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An iRGD-conjugated prodrug micelle with blood-brain-barrier penetrability for anti-glioma therapy.
    Lu L; Zhao X; Fu T; Li K; He Y; Luo Z; Dai L; Zeng R; Cai K
    Biomaterials; 2020 Feb; 230():119666. PubMed ID: 31831222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer.
    Yang J; Yang J; Wei Y; Yin H; Fang L; Chai D; Li H; Li H; Zhang Q; Zheng J
    Int Immunopharmacol; 2019 May; 70():125-134. PubMed ID: 30798161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis.
    Qian J; Zhou S; Lin P; Lei J; Zheng S; Xu W; Wang Y; Gao Z; Yang J
    Drug Dev Res; 2023 Jun; 84(4):654-670. PubMed ID: 36959702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
    Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
    Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving Antitumor Activity with N-Trimethyl Chitosan Entrapping Camptothecin in Colon Cancer and Lung Cancer.
    Sun L; Li X; Li Z; Li Z; Gou M; Qian Z; Peng F
    J Nanosci Nanotechnol; 2015 Sep; 15(9):6397-404. PubMed ID: 26716193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice.
    Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z
    Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redox-responsive amphiphilic camptothecin prodrug nanoparticles for targeted liver tumor therapy.
    Lu L; Li B; Lin C; Li K; Liu G; Xia Z; Luo Z; Cai K
    J Mater Chem B; 2020 May; 8(17):3918-3928. PubMed ID: 32227058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
    Hu C; Huang Y; Chen Y
    Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.
    Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS
    Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Delivery of Dual Anticancer Drugs Based on Self-Assembled iRGD-Modified Soluble Drug-Polymer Pattern Conjugate Nanoparticles.
    Li C; Chen Z; Zheng D; Zhao J; Lei J
    ACS Appl Bio Mater; 2021 Feb; 4(2):1499-1507. PubMed ID: 35014499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted rod-shaped mesoporous silica nanoparticles for the co-delivery of camptothecin and survivin shRNA in to colon adenocarcinoma in vitro and in vivo.
    Babaei M; Abnous K; Taghdisi SM; Taghavi S; Sh Saljooghi A; Ramezani M; Alibolandi M
    Eur J Pharm Biopharm; 2020 Nov; 156():84-96. PubMed ID: 32882423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multifunctional Nanotherapy for Targeted Treatment of Colon Cancer by Simultaneously Regulating Tumor Microenvironment.
    Zhang Q; Zhang F; Li S; Liu R; Jin T; Dou Y; Zhou Z; Zhang J
    Theranostics; 2019; 9(13):3732-3753. PubMed ID: 31281510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing of Intestinal Glycoprotein CD98 by Orally Targeted Nanoparticles Enhances Chemosensitization of Colon Cancer.
    Xiao B; Viennois E; Chen Q; Wang L; Han MK; Zhang Y; Zhang Z; Kang Y; Wan Y; Merlin D
    ACS Nano; 2018 Jun; 12(6):5253-5265. PubMed ID: 29860836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.